Finolex Cables Has Launched a New Product Namely ‘Finoultra’

 

Finolex Cables Limited is an Indian manufacturer of electrical and telecommunication cables based in Pune, Maharashtra. It is the flagship company of the Finolex Group, established in 1958. The company also manufactures polyvinyl chloride sheets for roofing, signage and interiors.

A New Era of Finolex Cables – FinoUltra

In today’s fast-paced world, staying connected is more crucial than ever. FinoUltra is engineered to meet the ever-growing demand for seamless, high-speed communication within the home. Whether it’s for work, entertainment, or staying in touch with loved ones, this state-of-the-art wired product ensures that you never miss a beat.

The FinoUltra isn’t just about functionality; it’s a perfect blend of aesthetics and performance. With its sleek, contemporary design, it complements any modern home. But the true beauty lies in its exceptional performance. Offering superior speed, stability, and security, it guarantees a flawless experience, whether you’re streaming, browsing, or engaging in video calls.

Why Choose FinoUltra?

Exceptional Reliability: A robust, wired connection for uninterrupted performance.

Lightning-Fast Speed: Optimised to handle high-demand tasks with ease.

Sleek, Modern Aesthetic: Designed to blend seamlessly into any home environment.

Durability: Built to endure, ensuring you get the most out of your investment.

Finolex Cables Q2 FY25 Results

In Q2 FY25, Finolex Cables reported a 10.90% rise in net consolidated total income, reaching ₹1,363.31 crore, up from ₹1,229.27 crore in the same quarter of the previous year. However, the company faced a 23.85% drop in net profit, which fell to ₹117.89 crore, compared to ₹154.81 crore in the previous year’s quarter. 

Share Price Performance 

At 1:52 PM today, Finolex Cables Ltd. shares traded at ₹1,007.90 per share on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Glenmark Life Sciences Name Has Been Changed to Alivus Life Sciences Ltd Effective From Jan 20, 2025

Glenmark Life Sciences, originally founded as a subsidiary of Glenmark Pharmaceuticals, specialises in developing, manufacturing, and supplying high-quality APIs to global markets. Over the years, it has built a strong reputation for advanced research, robust manufacturing, and a steadfast commitment to quality. Operating in over 80 countries, Glenmark Life Sciences is recognised for its reliability and innovation.

Glenmark Life Sciences Becomes Alivus Life Sciences

Glenmark Life Sciences has officially rebranded itself as Alivus Life Sciences Ltd., effective from January 20, 2025. This significant transformation reflects the company’s evolving vision, its commitment to excellence, and its ambition to redefine the landscape of the pharmaceutical and life sciences industries.

Glenmark Life Sciences Q2 FY25 Results

Glenmark Life Sciences reported its financial results for the Q2 FY25, recording a 15% year-on-year decline in revenue to ₹506.88 crore. The company’s net profit also fell by 20% year-on-year to ₹95.32 crore. This decline was primarily attributed to the temporary closure of its manufacturing facility in Ankleshwar, Gujarat, which affected revenue generation across various geographies. 

Despite the setback, the company remains optimistic about a recovery in the latter half of the fiscal year, supported by a robust order book and the resumption of operations at the affected facility.

Share Price and Performance 

At 12:49 PM today, Glenmark Life Sciences Ltd. shares traded at ₹1,043.15 per share on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Bandhan Mutual Fund Files For Fixed Maturity Plan – Series 209

Bandhan Mutual Fund has launched its Fixed Maturity Plan (FMP) – Series 209, a close-ended debt scheme with a tenure of 93 days. Units are priced at ₹10 during the New Fund Offer (NFO) period. Notably, the scheme will be listed on the Bombay Stock Exchange (BSE), ensuring liquidity for investors seeking to exit before maturity.

Investment Objective and Risk Class

The scheme aims to generate short-term income through a portfolio of debt and money market instruments maturing within the scheme’s tenure. Classified under the relatively low interest rate and moderate credit risk categories (B-I), the FMP aligns with conservative investor profiles. The benchmark index is the Nifty Ultra Short Duration Debt Index A-I.

Plans and Options Available

Two plans are offered: Regular and Direct. Both include growth and income distribution options, with the latter enabling payouts. If no selection is made, the growth option is the default. Investors have to adhere to the minimum subscription amount of ₹5,000 during the NFO period.

Portfolio Allocation and Restrictions

The scheme invests exclusively in debt and money market instruments, with a maximum allocation of 40% to securitised debt. It avoids high-risk instruments like derivatives, structured obligations, and foreign securities. Asset allocation complies with SEBI regulations to balance yield with safety.

Transparency in NAV and Costs

Net Asset Values (NAV) will be disclosed daily on Bandhan Mutual Fund’s website, AMFI’s portal, and the registrar’s platform, CAMS. The total expense ratio is capped at 1% of daily net assets for regular plans, with lower ratios for direct plans. 

No Premature Redemptions

As a close-ended scheme, units cannot be redeemed or repurchased before maturity. However, the BSE listing allows secondary market transactions for liquidity. The Bandhan FMP – Series 209 aims to provide consistent fixed-income returns within its short tenure, making it a structured option for conservative investors prioritizing capital preservation and low-risk returns.

Curious about your SBI SIP returns? Get accurate estimates of your investment growth using our SBI SIP Calculator and stay ahead of your financial goals.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Mutual Fund investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Stallion India Fluorochemicals IPO Opens January 16, 2025

Stallion India Fluorochemicals Limited, a seller of refrigerant and industrial gases, is set to launch its IPO to raise ₹199.45 crore. The issue includes a fresh issue of 1.78 crore shares worth ₹160.73 crore and an offer-for-sale (OFS) of 43.05 lakh shares aggregating ₹38.72 crore. The IPO will be open for subscription from January 16 to January 20, 2025.

Metrics Details
IPO Dates January 16, 2025, to January 20, 2025
Face Value ₹10 per share
Price Band ₹85 to ₹90 per share
Lot Size 165 shares
Total Issue Size ₹199.45 crore (2.22 crore shares)

Key Dates and Listing Details

The basis of allotment for Stallion India’s IPO will be finalized on January 21, 2025. Refunds and credit of shares to demat accounts are scheduled for January 22, 2025. The stock is expected to be listed on BSE and NSE on January 23, 2025. Investors must confirm their UPI mandate by 5 PM on the closing date, January 20, 2025.

Price Band and Lot Size

The price band for the IPO is set between ₹85 and ₹90 per share. Retail investors can apply for a minimum of one lot, comprising 165 shares, requiring an investment of ₹14,850. Small Non-Institutional Investors (sNII) can apply for a minimum of 14 lots (2,310 shares) amounting to ₹2,07,900, while Big Non-Institutional Investors (bNII) can bid for at least 68 lots (11,220 shares), requiring ₹10,09,800.

The net issue is allocated as follows: 50% for Qualified Institutional Buyers (QIBs), 35% for retail investors, and 15% for Non-Institutional Investors (NIIs).

Objects of the Issue

The proceeds will fund working capital needs, capital expenditures for semiconductor and refrigerant facilities, and general corporate purposes. The IPO is managed by Sarthi Capital Advisors, with Bigshare Services as the registrar.

About Stallion India Fluorochemicals Ltd 

Stallion India Fluorochemicals is into debulking, blending, and processing refrigerant and industrial gases. The company operates 4facilities, located in Maharashtra, Rajasthan, and Haryana, catering to industries such as semiconductors, pharmaceuticals, automotive, and electronics.

For the period ending September 30, 2024, the company reported a total revenue of ₹141.53 crore and a net profit of ₹16.57 crore. For FY24, its revenue stood at ₹236.23 crore with a profit of ₹14.79 crore.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

SIP vs. PPF: Evaluating Long-Term Investment Options

For individuals aiming to build a substantial corpus over the next 15 years, Public Provident Funds (PPF) and Systematic Investment Plans (SIPs) emerge as popular long-term investment options. While PPF is a government-backed savings scheme, SIPs are market-linked investment plans. Both options cater to different risk appetites and financial goals, making it essential to understand their features and returns.

Comparative Analysis – Between SIPs and PPFs

When comparing SIPs (₹6,666/month) and PPFs (₹80,000/year), the distinction lies in their nature and returns. 

The table below shows a yearly investment of ₹80,000 in PPF with returns of 7.1%. In the 1st year, the total value at the end of the year is ₹85,680. By the end of the 15-year period, the total value stands at ₹21,69,712.

 

Year Amount Deposited in ₹ Returns @7.1% Total Value at the end of the year in ₹
1 80,000 5,680 85,680
2 1,60,000 17,444 1,77,444
3 2,40,000 35,722 2,75,722
15 12,00,000 9,69,712 21,69,712

In the table below, we have shown a SIP of ₹6,666 per month, which translates to a total investment of ₹79,992 in the 1-year and in the 2-year would be ₹1,59,984. Assuming a return of 12%, the total value at the end of the year in 1 year is ₹85,387, and in the 15th year, it would be ₹33,63,504 as compounding works its magic over the long term. 

Year SIP Amount per month in ₹ Total Amount Invested in ₹ Returns @12% Total Value at the end of the year in ₹
1 6,666 79,992 5,395 85,387
2 6,666 1,59,984 21,619 1,81,603
3 6,666 2,39,976 50,046 2,90,022
15 6,666 11,99,880 21,63,624 33,63,504

After conducting a comparative analysis, it is evident that over a 15-year period, an SIP investment would generate a total corpus of ₹33,63,504. This includes an investment of approximately ₹12,00,000 and returns amounting to ₹21.63 lakh. On the other hand, if the same ₹12,00,000 were invested in a PPF (Public Provident Fund) at a return rate of 7.1%, the total corpus would grow to ₹21.69 lakh, with gains of ₹9.69 lakh.

Disclaimer: This blog has been written exclusively for educational purposes. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Mutual Fund investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Government Shareholding Structure After ₹2,000 Crores QIP

As per reports, The government has approved a stake sale plan for 5 state-run banks, involving a Qualified Institutional Placement (QIP) worth ₹2,000 crore each. This plan aims to enhance the financial position of these lenders while reducing the government’s stake.

QIP and Shareholding Impact

The banks included in the plan are the Bank of Maharashtra, UCO Bank, Indian Overseas Bank, Central Bank of India, and Punjab & Sind Bank. The QIP will result in a reduction of government holdings, with Punjab & Sind Bank expected to see the highest dilution and Indian Overseas Bank the lowest based on current market prices. The Offer for Sale (OFS) details remain undisclosed, but the QIP will pave the way for these banks to meet regulatory shareholding norms.

Bank Government Stake(%) Post QIP(%)
Bank of Maharashtra 79.6 75.69
Punjab & Sind Bank 98.25 92.27
IOB 96.38 94.44
UCO Bank 95.39 91.87
Central Bank of India 93.08 89.11

Improvement in CRAR and Beneficiaries

Post the successful QIP, the Capital to Risk Assets Ratio (CRAR) of these banks is expected to improve by 100 to 300 basis points. Punjab & Sind Bank is likely to benefit the most from the increase, while the Central Bank of India’s tier-I ratio will see a comparatively smaller impact. These enhancements will strengthen the financial health and operational stability of the banks involved.

Bank Current Tier 1 Ratio(%) Tier 1 Post QIP(%)
Bank of Maharashtra 13.13 14.43
Punjab & Sind Bank 14.55 17.57
IOB 14.75 16.07
UCO Bank 14.59 16.10
Central Bank of India 14.01 15.0

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Capital Numbers Infotech IPO to Open on January 20

Capital Numbers Infotech, a digital consulting and IT engineering services provider, is set to launch its ₹169.37 crore initial public offering (IPO) on January 20, 2025, with anchor book subscriptions opening on January 17, 2025. The company’s shares are expected to debut on the BSE SME platform on January 27, 2025.

IPO Details Information
IPO  Dates January 20, 2025 to January 22, 2025
Price Band ₹250 – ₹263 per share
Face Value ₹10 per share
IPO Size ₹169.37 crore
Lot Size 400 shares

IPO Structure and Pricing

The IPO comprises a fresh issue of 32.2 lakh shares worth ₹84.69 crore and an offer-for-sale (OFS) of 32.2 lakh shares, also aggregating to ₹84.69 crore. The price band for the issue is set at ₹250-₹263 per share, with a minimum lot size of 400 shares. Retail investors can invest a minimum of ₹1,05,200, while high-net-worth individuals (HNIs) must apply for at least two lots, totallingtotaling ₹2,10,400.

GYR Capital Advisors Private Limited is the lead manager for the issue, while Link Intime India Private Ltd serves as the registrar.

Key Financials

For the fiscal year ending March 31, 2024, the company reported a net profit of ₹26 crore, showing a 50% growth from ₹17.35 crore in the previous fiscal. Revenue grew 6% during the same period, rising from ₹92.6 crore to ₹98.2 crore. As of September 30, 2024, Capital Numbers Infotech recorded a profit of ₹13.67 crore on revenue of ₹50.2 crore.

Use of Proceeds

The proceeds from the fresh issue will be utilized for technological upgrades, business development, investments in subsidiaries, and potential acquisitions. Additionally, funds will be allocated for general corporate purposes.

Company Overview

Incorporated in 2012, the West Bengal-based company provides software development solutions, including digital engineering, data analytics, AI/ML, and mobile app development. 

The company is led by promoters Mukul Gupta, Vipul Gupta, and Herprit Gupta, who collectively hold 99.99% of the pre-issue shareholding. Post-issue, the promoter group’s shareholding will be diluted.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Hindustan Zinc Hit With ₹92.55 Crore GST Penalty in Rajasthan

Vedanta Group’s Hindustan Zinc Ltd (HZL) has found itself in a tax dispute, with penalties amounting to ₹92.55 crore levied by the Deputy Commissioner of State Tax, Udaipur. The case revolves around input tax credit claims under Section 17(5) of the GST law for two financial years 2018-19 and 2019-20.

What Happened?

The penalties are divided into ₹41.11 crore for FY 2018-19 and ₹51.45 crore for FY 2019-20. Orders dated January 13, 2025, were received by the company on the same day. The orders also include a tax demand and applicable interest for the disputed years.

HZL’s Take

Hindustan Zinc has decided to appeal the orders. The company plans to file its challenge with the Appellate Authority within the timeframe laid out under GST rules. According to their exchange filing, HZL doesn’t anticipate this issue having any major impact on its financial health or operations.

Market Performance

Despite the penalties and ongoing tax dispute, HZL’s shares performed well on January 14, 2025, closing at ₹436.25, a 3.98% jump. Today, Hindustan Zinc Ltd shares were trading at ₹441.90 as of 1:58 PM, showing a 1.34% intraday gain, while declining 33.02% over the past six months and rising 37.34% over the past year.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

L&T Launches Second Multi Purpose Vessel for Indian Navy

Larsen & Toubro (L&T) has launched the Indian Navy’s second Multi-Purpose Vessel (MPV), INS Utkarsh, from its Kattupalli Shipyard near Chennai. This launch comes just three months after the first MPV, INS Samarthak, and is a step in expanding the country’s Navy fleet. INS Samarthak is currently undergoing tests and trials before being handed over to the Navy.

Multi-Purpose Capacity

Designed to handle a range of tasks, the MPVs are 107 meters long, 18.6 meters wide, and have a displacement of over 3,750 tonnes. These vessels are built for maritime surveillance, humanitarian assistance, pollution control, and as platforms for testing next-generation weapons and sensors. They are also equipped to launch and recover various surface and aerial assets.

Launch Event and Participants

The launch of INS Utkarsh was officiated by Dr. Sushmita Misra Singh, the wife of Union Defence Secretary Rajesh Kumar Singh. The event was attended by senior officials from the Navy, including Vice Admiral B. Sivakumar and Rear Admiral Vishal Bishnoi, alongside L&T representatives.

Built at Kattupalli Shipyard

Both MPVs were designed and engineered at L&T’s Warship Design Centre in Chennai and constructed at the Kattupalli Shipyard. The shipyard is known for its shipbuilding and repair facilities, equipped with ship lifts and berths capable of handling multiple projects simultaneously.

Other Projects in Progress

Beyond these MPVs, L&T is also working on three Cadet Training Ships and six additional vessels for the Navy. Repairs for the Indian naval ship INS Tir are currently underway at the same shipyard. This launch shows the capacity of India’s shipbuilding sector, aligning with national initiatives to develop homegrown defence technology.

Larsen & Toubro Ltd shares were trading at ₹3,498.15 as of 2:08 PM on January 15, up ₹35.55 (1.03%) for the day, but showing a decline of 4.20% over the past six months and 1.27% over the past year.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Tata Group Partners with IISc to Establish Tata IISc Medical School

The Tata Group has joined hands with the Indian Institute of Science (IISc) to establish the Tata IISc Medical School at the IISc Bengaluru campus. Marking a significant milestone, this initiative focuses on fostering innovation and excellence in medical education and research. An MoU was signed on January 14, with Tata Group committing Rs 500 crore to support this endeavour.

Transforming Healthcare through Innovation

Chairman of Tata Sons, N Chandrasekaran, emphasised the critical role of technology in addressing India’s healthcare challenges. Highlighting the transformative potential of this collaboration, he stated that the institute would focus on integrating modern technology with healthcare to address issues spanning from diagnosis to community health. The school aims to build a new generation of physician-scientists equipped with advanced skills and global perspectives, facilitating breakthroughs in medical science.

A Legacy of Excellence and Vision

IISc Director, Prof G Rangarajan, described the partnership as a continuation of the century-old legacy shared by the Tatas and IISc. He acknowledged Jamsetji Nusserwanji Tata’s visionary philanthropy, which led to the establishment of IISc and underscored its commitment to advancing education and research. The Tata IISc Medical School will offer integrated MD-PhD and dual-degree programs, training students in both medical practice and scientific research. The initiative aims to create affordable healthcare solutions while fostering cutting-edge innovation in medicine and technology.

Conclusion

By combining IISc’s scientific expertise with the Tata Group’s philanthropic vision, The establishment of the Tata IISc Medical School marks a transformative step in India’s healthcare and education sectors. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.